Cramer Remix: Another speculative biotech with tremendous upside
September 19, 2016 at 19:08 PM EDT
Jim Cramer eyed the biotechs after Sarepta Therapeutics rally, and found another attractive spec that could boost portfolios.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|